GPATCH3: A Potential Drug Target and Biomarker (G63906)

GPATCH3: A Potential Drug Target and Biomarker

G-patch domain containing 3 (GPATCH3) is a gene located on chromosome 16q24. It is a small non-coding RNA molecule that has been shown to play a role in various cellular processes, including cell adhesion, migration, and invasion. patch domain containing 3 has also been implicated in the development and progression of various diseases, including cancer. As a result, G-patch domain containing 3 has emerged as a promising drug target and biomarker.

The G-patch domain containing 3 genes has four exons, which encode a 23 amino acid protein. This protein is composed of a N-terminal transmembrane domain, a catalytic domain, and a C-terminal cytoplasmic domain. The N-terminal transmembrane domain is responsible for the protein's ability to interact with various cell surface molecules, while the catalytic domain is responsible for the protein's catalytic activity. The C-terminal cytoplasmic domain is responsible for the protein's ability to interact with intracellular signaling molecules.

G-patch domain containing 3 has been shown to play a role in cell adhesion and migration. G-patch domain containing 3 has been shown to interact with the protein Integrin, which is a transmembrane protein that is involved in cell adhesion. and migration. The interaction between G-patch domain containing 3 and Integrin has been shown to promote the growth and migration of various cell types. This suggests that G-patch domain containing 3 may be a drug target that can be targeted with small molecules or antibodies to inhibit its function.

G-patch domain containing 3 has also been shown to be involved in the development and progression of various diseases, including cancer. Many studies have shown that G-patch domain containing 3 is overexpressed or hypermethylated in various types of cancer, including breast, ovarian , and colorectal cancer. The overexpression or hypermethylation of G-patch domain containing 3 has been shown to promote the growth and survival of cancer cells, suggesting that it may be a useful biomarker or drug target in cancer treatment.

In addition to its role in cell adhesion and migration, G-patch domain containing 3 has also been shown to play a role in the regulation of cell cycle progression. The G-patch domain containing 3 protein has been shown to interact with the protein p21 (TOR), which is a transcription factor that is involved in the regulation of cell cycle progression. The interaction between G-patch domain containing 3 and p21 has been shown to promote the growth and proliferation of various cell types, suggesting that G-patch domain containing 3 may be a drug target that can be targeted with small molecules or antibodies to inhibit its function.

The G-patch domain containing 3 has also been shown to play a role in the regulation of cellular signaling pathways. The G-patch domain containing 3 protein has been shown to interact with the protein FAK (focal adhesion kinase), which is a protein that is involved in the regulation of cell signaling pathways. The interaction between G-patch domain containing 3 and FAK has been shown to promote the formation of focal adhesion clusters, which are thought to play a role in the regulation of cellular signaling pathways.

In conclusion, G-patch domain containing 3 is a gene that has been shown to play a role in various cellular processes, including cell adhesion, migration, and invasion. Its interaction with Integrin, p21, and FAK suggests that it may be a drug target or biomarker for various diseases, including cancer. Further research is needed to fully understand the function of G-patch domain containing 3 and its potential as a drug target or biomarker.

Protein Name: G-patch Domain Containing 3

Functions: Involved in transcriptional regulation. It is able to activate transcription from the CXCR4 promoter and therefore it might control neural crest cell migration involved in ocular and craniofacial development (PubMed:28397860). Is a negative regulator of immune antiviral response, acting via down-regulation of RIG-I-like receptors signaling and inhibition of type I interferon production. The control mechanism involves interaction with mitochondrial MAVS and inhibition of MAVS assembly with downstream proteins implicated in antiviral response, such as TBK1 and TRAF6 (PubMed:28414768)

More Common Targets

GPATCH4 | GPATCH8 | GPBAR1 | GPBP1 | GPBP1L1 | GPC1 | GPC1-AS1 | GPC2 | GPC3 | GPC4 | GPC5 | GPC5-AS1 | GPC5-AS2 | GPC6 | GPC6-AS1 | GPC6-AS2 | GPCPD1 | GPD1 | GPD1L | GPD2 | GPER1 | GPHA2 | GPHB5 | GPHN | GPI | GPI transamidase complex | GPI-GlcNAc transferase complex | GPIHBP1 | GPKOW | GPLD1 | GPM6A | GPM6B | GPN1 | GPN2 | GPN3 | GPNMB | GPR101 | GPR107 | GPR108 | GPR119 | GPR12 | GPR132 | GPR135 | GPR137 | GPR137B | GPR137C | GPR139 | GPR141 | GPR142 | GPR143 | GPR146 | GPR148 | GPR149 | GPR15 | GPR150 | GPR151 | GPR152 | GPR153 | GPR155 | GPR156 | GPR157 | GPR158 | GPR158-AS1 | GPR15LG | GPR160 | GPR161 | GPR162 | GPR17 | GPR171 | GPR173 | GPR174 | GPR176 | GPR179 | GPR18 | GPR180 | GPR182 | GPR183 | GPR19 | GPR199P | GPR20 | GPR21 | GPR22 | GPR25 | GPR26 | GPR27 | GPR3 | GPR31 | GPR32 | GPR33 | GPR34 | GPR35 | GPR37 | GPR37L1 | GPR39 | GPR4 | GPR42 | GPR45 | GPR50 | GPR52 | GPR55